Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI

Sponsor
Collegium Medicum w Bydgoszczy
Study ID
NCT07231939
Status
Recruiting
Apply to this trial

Conditions

  • Acute Kidney Injury
  • Contrast-Induced Acute Kidney Injury
  • Coronary Artery Disease
  • Percutaneous Coronary Intervention

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Flozin — DRUG
    Patients who underwent percutaneous coronary interventions while using empagliflozin or dapagliflozin

Study Details

All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion. The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available. The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.

Key Dates

First listed
Nov 17, 2025
Start date
Nov 1, 2025
Status verified
Oct 2025
Primary completion
Dec 31, 2025
Completion
Mar 31, 2026

Study Design

Enrollment
4,000 participants (estimated)

Arms

  • Arm: Patients using any flozin at the time of coronary intervention
    Patients who underwent percutaneous coronary procedures while using empagliflozin or dapagliflozin in a standard 10 mg daily dose
  • Arm: Patients not using any flozin
    Patients who underwent percutaneous coronary interventions but were not using any flozins

Primary Outcome Measure

Occurrence of Contrast-Induced Acute Kidney Injury (CI-AKI) [ Time Frame: 0-72 hours ]

Central Contacts

Related Studies